porporanty.						
All rights reserved	No reuse allowed without permission.					
/ge						

1	A prebiotic diet intervention can restore faecal short chain fatty acids in
2	Parkinson's Disease yet fails to restore the gut microbiome homeostasis
3	
4	Janis Rebecca Bedarf <sup>1, 2, 3</sup> , Stefano Romano <sup>3</sup> , Silke Sophie Heinzmann <sup>4</sup> , Anthony
5	Duncan <sup>3,5</sup> , Maria H. Traka <sup>6</sup> , Duncan Ng <sup>6</sup> , Daniella Segovia-Lizano <sup>6</sup> , Marie-Christine
6	Simon <sup>7</sup> , Arjan Narbad <sup>3</sup> , Ullrich Wüllner <sup>1,2</sup> , Falk Hildebrand <sup>3,5</sup> .
7	
8	1 Dept. of Movement Disorders (PSB), Centre of Neurology, University Hospital
9	Bonn, Germany
10	2 German Centre for Neurodegenerative Diseases, DZNE Bonn, Germany
11	3 Food, Microbiome, and Health Institute Strategic Programme, Quadram Institute
12	Bioscience, Norwich Research Park, NR4 7UQ Norwich, Norfolk, UK
13	4 Research Unit Analytical BioGeoChemistry, Helmholtz Center Munich,
14	Neuherberg, Germany
15	5 Decoding Biodiversity, Earlham Institute NR4 7UZ Norwich, Norfolk, UK
16	6 Food & Nutrition National Bioscience Research Infrastructure, Quadram Institute
17	Bioscience, Norwich Research Park, NR4 7UQ Norwich, Norfolk, UK
18	7 Institute of Nutritional and Food Sciences (IEL), Nutrition and Health, University of
19	Bonn, Germany
20	
21	
22	Corresponding authors:
23	Dr Falk Hildebrand: falk.hildebrand@quadram.ac.uk
24	Dr. Janis Rebecca Bedarf: janis.bedarf@ukbonn.de
25	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 26 ABSTRACT

Despite extensive research, current treatment of Parkinson's Disease (PD) remains
symptomatic and disease modifying approaches are urgently required. A promising
approach is to target the gut-brain-axis by modifying the intestinal microbiota and the
herein produced metabolites.

We decided to test this approach by modifying key metabolites of bacterial intestinal fermentation: short chain fatty acids (SCFA), known to be decreased in PD patients.

A prospective, controlled pilot study was conducted in 11 couples, with one PD patient and healthy spouse as control (CO) each. Participants followed a 4-week diet rich in dietary fibre in addition to the intake of a prebiotic sirup (Lactulose). Metagenomes and metabolites of the gut microbiota, urinary metabolites and clinical characteristics were assessed.

The short-term dietary intervention significantly augmented gastrointestinal SCFA 38 production, likely associated with increased Bifidobacteria spp. PD associated 39 gastrointestinal symptoms improved with increasing SCFA levels. The pre-existing 40 bacterial dysbiosis associated with PD, such as depletion of genera *Blautia*, *Dorea*, 41 and *Erysipelatoclostridium* in PD, persisted within the study period. Some pathobionts, 42 i.e. *Klebsiella*, were reduced after the intervention. Bacterial metabolite composition 43 (both faecal and urine metabolomes) shifted towards the composition of the healthy 44 control in PD after the intervention. Among these brain-relevant gut metabolic 45 functions improved in PD patients, such as S-Adenosyl methionine (SAM), 3,4-46 Dihydroxyphenylacetic acid (DOPAC), Glutathione (GSH), Tryptophan and inositol 47 related changes, involved in neuroprotective and antioxidant pathways. 48

Despite the small cohort size and short-term study period a minor dietary intervention
 was sufficient to improve gastrointestinal symptoms in PD and altered metabolic

# 51 parameters in a presumed neuroprotective manner, warranting further investigation in

52 larger cohorts.

## 53 Introduction

The human gut microbiota form a complex community with high taxonomic diversity 54 and complex metabolic activity. The bi-directional microbiota-related gut-brain 55 signalling has emerged as an important factor in human brain (patho-)physiology<sup>1</sup>. The 56 gut microbiome is involved in immune homeostasis and might have a role in the 57 development or progression of neuro-psychiatric diseases, including multiple 58 sclerosis, Alzheimer's and Parkinson's disease (PD)<sup>2,3</sup>. The early involvement of the 59 gastro-intestinal tract in PD – sometimes preceding motor symptoms for years – has 60 been linked to the intestinal dysbiosis in multiple independent cohorts (reviewed in<sup>4,5</sup>). 61 Taxonomic alterations hinted at impairments of the intestinal barrier and altered 62 immune function as well at metabolic changes<sup>6</sup> but it remains unclear, whether these 63 changes are the causes or consequences of disease. 64

Among the variety of metabolites that have been shown to beneficially impact both 65 intestinal barrier and blood brain barrier (BBB)-integrity<sup>7-9</sup>, short chain fatty acids 66 (SCFA, represented mainly by butyrate, propionate, and acetate, and fermented from 67 dietary fibres<sup>10</sup>) seem to play a pivotal role. For example, SCFA's can directly influence 68 the colonic epithelium, act as major energy substrates for colonocytes and promote 69 tight junction proteins and neuronal activation through stimulation of G protein-70 coupled receptors<sup>11,12</sup>. Administration of butyrate in transgenic animal models of PD 71 improved motor deficits, reduced inflammation and alleviated dopamine deficiency<sup>13,14</sup> 72 and together with a high-fibre diet, reduced markers of cerebral inflammation in aged 73 mice<sup>1516</sup>. SCFAs may thus present a link between gut microbiota dysbiosis and 74 neurodegenerative alterations<sup>12</sup>. In line with a concept of anti-inflammatory and 75 neuroprotective effects of SCFA, studies in human PD found depleted faecal SCFA 76 concentrations and reduced abundance of SCFA producing bacteria compared with 77

healthy controls<sup>17,18</sup>. Moreover, an integrated study examining both faecal and plasma
SCFA levels, suggested that SCFAs may even reflect disease severity and could thus
serve as a surrogate marker for PD<sup>19</sup>. In concordance with this data, a high fibre
'mediterranean' diet was reported to decrease the risk for PD<sup>20,21</sup>, in comparison to a
low fibre, high caloric 'western' diet<sup>22,23</sup>.
Altering the microbiome composition and metabolism through dietary interventions

84 might thus evolve as a therapeutic option to protect against or modulate the course of

PD and other neurodegenerative diseases  $^{24,25}$ . We here investigated whether a dietary

intervention designed to prebiotically enrich colonic SCFA production would alter
 faecal SCFA concentrations and ameliorate gut microbiome dysbiosis as well as

- 88 gastrointestinal symptoms in PD.
- 89

# 90 Results

# 91 **Participants and clinical measures**

All rights reserved. No reuse allowed without permission.

- 92 10 of 11 enrolled couples (each consisting of 1 PD and 1 CO) completed the study
- 93 (clinical characteristics and dietary baseline information in Suppl. Table 1) and

	PD	CO	p-value
Age (yrs)	64.73 ± 8.92	61.18 ± 7.92	p=0.31
Sex (f/m)	3/8	8/3	p=0.09
BMI (kg/m²)	26.81 ± 4.64	27.48 ± 4.71	p=0.72
Smoking [yes/past/never]	0/6/5	1/7/3	p=0.66
Levodopa [yes/no]	7/4	0/0	p=0.02
Dopamine-Agonist [yes/no]	10/1	0/0	P<0.0001
MAO-Inhibitor [yes/no]	1/10	0/0	p=0.48
COMT-Inhibitor [yes/no]	2/9	0/0	p=1
Statine intake [yes/no]	1/10	1/10	p=1
Diet omnivor	11	11	p=1
Probiotics at baseline			
Yes No	0 10	2 9	p=1
sometimes	1	0	
Dairy consumption at baseline			
<1/d	6	9	p=0.36
2-3/d NS	4 1	2 0	F
Vegetable consumption at	I	0	
baseline			
<1/d	1	0	
2-3/d	7	9	0.50
3-4/d	1	2	p=0.59
5 or more/d	1	2 0	
NS	1	0	

#### Suppl. Table 1 Clinical characteristics and dietary baseline information

Dietary baseline information was acquired by a questionnaire assessing the dietary habits of the participants before the intervention; Note that one couple dropped out of the study after baseline measurements due to non-study related reasons; BMI, body mass index; PD, Parkinson's disease; CO, healthy control; Data is presented as mean ± standard deviation or absolute numbers of participants; NS, not specified.

- 94 performed the dietary intervention for 4 weeks (Fig. 1a). One couple dropped out of
- the study before the second visit due to non-study related reasons. PD patients were
- 96 mild to moderately advanced (Hoehn and Yahr 1-2).


No serious adverse events occurred. Some participants (N=4 PD and N=4 CO) had tolerable bloating when starting the dietary intervention, which ceased during the study (self-reported); no diarrhea was reported. Safety parameters (sodium, potassium, Creactive protein, and thyroid-stimulating hormone) were comparable between groups before prebiotics and there were no changes after prebiotics. All participants followed an omnivorous diet prior to the study with occasional intake of probiotics in 3 subjects (n=1 PD and n=2 CO, Suppl. Table 1).

To measure the participants' compliance to the dietary recommendations, a food adherence score was calculated based on the recommended consumption of raw apples (see methods). This showed overall good adherence throughout the study cohort; four participants (n=2 CO and n=2 PD subjects, of whom 2 belong to one couple) had less compliance with our dietary intervention. (Suppl. Fig. 1a).

The average fibre intake during the intervention was similar in both CO and PD (median 25.1 g/d and 23.5 g/d, respectively, Suppl. Fig. 1b). Although this is below the recommended daily intake of 30 g/d in Germany, it is still above average reported levels in Germany of 23 g/d and 20 g/d for males and females, respectively<sup>26</sup>.

113

All rights reserved. No reuse allowed without permission.



p>0.05).

114 UPDRS<sub>III</sub>, as a measure of the PD disease severity, was slightly reduced after the

115 prebiotic intervention (Wilcoxon signed-rank test, p>0.05, Fig. 1b). While


116 gastrointestinal symptoms (sum score of the modified GSRS) were significantly higher

in PD patients compared to CO before prebiotics, no significant difference could be

observed after prebiotics (Wilcoxon rank sum test, p=0.025 and p=0.48, respectively,

- Fig. 1b); however, this could be related to increasing GIT symptoms in the CO, mostly
- related to constipation and bloating. Stool frequency (as a sub measure of the GSRS)


- 121 was sign. differed between PD and CO and this did not change during diet intervention
- 122 (Wilcoxon rank sum test, p=0.043 and p=0.007, respectively, Fig. 1b). Faecal markers



sizes; D partial correlation of SCFA concentrations with clinical measure shows a sign. inverse correlation of Acetate, Propionate, and Butyrate with disease severity measured with UPDRSIII, while stool frequency was inversely correlated to Propionate, Butyrate, and Valerate. GSRS shows a sign. negative correlation with Butyrate and Valerate, red= positive and blue= negative correlation, numbers indicate the correlation coefficient r.

- of intestinal inflammation (Calprotectin) or intestinal permeability (Alpha-1-Antitrypsin,
- 124 Suppl. Fig. 1c) were comparable between study groups and remained unchanged after
- 125 prebiotics.
- 126 The prebiotic diet increased faecal SCFA levels and improved gastro-intestinal
- 127 functioning in PD
- 128 Faecal SCFA concentrations were lower in PD subjects at baseline (Wilcoxon rank
- sum test, p<0.05, q>0.1), note that baseline SCFA results were comparable between
- targeted SCFA measures (Fig. 1c) and SCFA based on metabolomics (Suppl. Fig.
- 131 2a). The short-term dietary intervention increased concentrations of most SCFAs

All rights reserved. No reuse allowed without permission.



composition between PD and CO before and after prebiotics show that SCFA composition equalizes after prebiotics (perMANOVA, before R<sup>2</sup>=0.13, p=0.08, after R<sup>2</sup>=0.01, p=0.8, unconstrained dbRDA, Euclidean distance, targeted SCFA measures).

133 (Fig. 1c), as the statistical power was likely limited by cohort size.

134 Considering effect sizes (borders in Fig. 1c), the increase in several SCFA 135 concentrations was markedly greater in PD than in CO, possibly related to an 136 increased Lactulose intake in the PD group.

Multivariate testing of the SCFA composition between PD and CO either before or after the diet intervention revealed fewer dissimilarities after prebiotics (perMANOVA before R<sup>2</sup>=0.13, p=0.08, and after R<sup>2</sup>=0.01, p=0.8, respectively, Suppl. Fig. 2b), indicating that the SCFA profile of PD patients adapted to a healthy state after prebiotics.

Stool frequency, modified GSRS, and PD disease severity were inversely correlated with several SCFA including butyrate, in PD patients (Fig. 1d), suggesting that increased SCFA concentrations were linked with better gastro-intestinal functioning and reduced disease symptoms.

146 The prebiotic diet enhanced beneficial Bifidobacteria in both study groups yet

147 failed to restore the dysbiosis associated with PD

All 40 faecal samples from 20 participants and two time points each, were sequenced using short read metagenomics. MGS (metagenomic species) dereplicated from MAGs (metagenomics assembled genomes) were used to obtain the taxonomic composition for all samples.


Species level alpha diversity was comparable between study groups, however, richness and diversity decreased after prebiotics (only sign. for CO, Wilcoxon signedrank test, p=0.02, Suppl. Fig. 3a). The genera *Bifidobacteria, Bacteroides, Faecalibacterium, Blautia A,* and *Phocaeicola* dominated the overall taxonomic composition (Suppl. Fig. 3b).

157	Most of the species level differences in faecal sample composition were driven by
158	household (R <sup>2</sup> = 0.47, p<0.001, perMANOVA, dbRDA), i.e., most samples of the same
159	household clustered together (Fig. 2a). Disease status (PD vs.CO) and diet
160	intervention (before vs. after prebiotics) explained only 9.8% of total variance together
161	(Fig. 2b and c). This "household-effect" was the prevalent source of variation between
162	individual gut microbiomes at all taxonomic levels (R2 = $0.41 - 0.47$ ) as well as
163	functional potential and metabolomics profiles (R2 = 0.36 – 0.47, Suppl. Table 2).

Data	R²	p-value
MGS Species	0.46	<0.001
Species	0.46	<0.001
Genus	0.47	<0.001
Family	0.44	<0.001
Order	0.46	<0.001
Class	0.41	<0.001
Phylum	0.41	<0.001
Functional metabolic potential (KEGG, general)	0.42	<0.001
Functional metabolic potential (KEGG/GBM, brain-relevant)	0.49	<0.001
Urine metabolomics	0.36	<0.001
aeces metabolomics	0.45	<0.001

164

For our further analysis we therefore consequently used statistics conditioned for household effect. An ordination conditioned by household revealed that the dissimilarity in taxonomic composition was driven by differences between PD and CO



#### Figure 2 Household-effect and taxonomic differences between PD and CO

A, the dbRDA shows a strong clustering of metagenomes by household, i.e. from PD with their respective healthy spouse/CO, further termed "household-effect"; this effect explained 46% of data variability on MGS species level; B, dbRDA conditioned for households reveals a sign. difference in taxa dissimilarity between PD and CO after prebiotics, but not before prebiotics; C, top 15 correlated taxa (MGS species) between the constrained dbRDA (conditioned for households) and study group (PD/CO) or diet intervention (before/after prebiotics), indicating a strong association of different *Bifidobacteria spp*. with the intervention. D and E, several genera were markedly reduced in the PD group after prebiotics, paralleled by several trends, e.g., enrichment in *Eubacterium F* and *Methanobrevibacter\_A* in PD; some of these Genera already tended to differ before prebiotics (p<0.05, but q> 0.1 before prebiotics; p<0.05, q<0.1 after prebiotics; data in D is presented with p-values generated by univariate tests between PD and CO on a log scaled axis, Wilcoxon signed-rank test; data in E is presented as relative abundance of the different Genera). \* = p<0.05, q<0.1.


subjects ( $R^2=0.27$ , p<0.001, permutation test), or differences between before and after prebiotics ( $R^2=0.2$ , p<0.001, permutation test, Fig. 2b and c):

Several taxa were identified representing the previously documented PD dysbiosis, 170 including Akkermansia muciniphila and Prevotella spp. (sp900313215) enriched in PD 171 subjects, while Bacteroides fragilis and Anaerostipes hadrus were enriched in CO (Fig. 172 2c). The strongest signal relating to diet intervention was an enrichment of several 173 174 Bifidobacteria spp. after prebiotics in both CO and PD (multivariate and univariate tests, Fig. 2c, Fig. 3a, and Suppl. Fig. 3c). In PD patients, we observed a significant 175 176 enrichment in six different Bifidobacteria spp., four of which were also increased in CO after prebiotics (Fig. 3a and Suppl. Fig. 3c Wilcoxon signed-rank test). Similarly, 177 UMGS1975 (Christensenellales) was enriched after prebiotics in both groups, but 178 more so in PD subjects that were also enriched for UMGS1975 before the intervention. 179

#### All rights reserved. No reuse allowed without permission.

## 180 Streptococcus thermophilus was reduced only in the PD group after the diet

## 181 intervention.



#### Suppl. Figure 3, Richness and bifidogenic effect of the prebiotic intervention

A, Species level alpha diversity was not sign. different between PD and CO. However, within the CO group, species richness decreased after prebiotics (p=0.02, Wilcoxon signed-rank test); B, Composition of the top 10 Genera, separated for PD and CO; C, before vs. after comparisons (Wilcoxon signed-rank test revealed that several Bifidobacteria spp. increased after prebiotics, boxplots show relative abundance of taxa. n=6 *Bifidobacteria spp.* were enriched in PD after prebiotics, of which n=4 were also enriched in CO individuals; n=2 taxa were only sign. different in PD (Strept. Thermophilus, UMGS1975).


183

The PD-associated dysbiosis was not compensated by the diet intervention: Blautia, 184 Dorea, UBA1191 (Anaerovoracaceae) and Erysipelatoclostridium remained depleted 185 in PD and UMGS1975 (Christensenellales) remained increased in comparison to CO 186 before and after prebiotics (all p<0.05, q> 0.1 before prebiotics; p<0.05, q<0.1 after 187 prebiotics, Wilcoxon rank sum test, Fig. 2d and 2e). This was also reflected in a 188 markedly different species composition between PD and CO after prebiotics 189 (perMANOVA, R<sup>2</sup>=0.08, p=0.03 and R<sup>2</sup>=0.05, p=0.16, after and before, respectively, 190 Fig. 2b). Notably, some subjects had elevated levels of genus Klebsiella (p>0.05), 191 192 which decreased after prebiotics. Since this genus contains several pathobionts, this could be a benefit provided by prebiotics. 193 Alternatively, we cannot exclude that the high abundance of Klebsiella in some 194

195 samples was due to inadequate anaerobic conditions during sample collection or196 storage.

197

- 198 To assess the extent of dysbiosis further, we assessed common bacterial guilds of
- the human gut microbiome (represented through Enterosignatures, ES) and their
- prevalence in our samples<sup>27</sup>. Overall, both study groups showed a good ES model



#### Figure 3, Gut bacterial communities affected by the prebiotic diet intervention

A, several taxa were significantly different between before and after prebiotics tests in both groups; n=6 *Bifidobacteria spp.* were enriched after prebiotics in PD, of which n=4 were also enriched in CO individuals; n=2 taxa are only changed in PD (Strept. Thermophilus, UMGS1975, data is presented as p-values generated with univariate tests/ Wilcoxon signed-rank test between before and after prebiotics on log scaled axes); B, ES composition shifted towards increased ES-Bifi in both groups while ES-Firmi decreased (sign. only in PD group, Wilcoxon rank sum test; C, top 15 KEGG modules in relation to the study group (PD/CO and diet intervention (before/after prebiotics), constrained dbRDA, conditioned for household), shows a strong correlation of fatty acid (FA) metabolism with the intervention (permutation test, R<sup>2</sup>=0.3, p<0.001) as well as several functions correlated to either PD or CO (permutation test, R<sup>2</sup>=0.16, p<0.001, SPL, Saccharide, Polyol and lipid transport System); D, Differences in KEGG Modules before vs. after prebiotics (relative abundance, Wilcoxon signed-rank test), increased microbial genes related to fatty acid metabolism after prebiotics were similarly observed in PD and CO subjects (upper panel), on the other hand several genes were only changed in PD (lower panel). \* = p<0.05, \*\* = p<0.01 (AA, amino acid).

fit, comparable between both groups (Suppl. Fig. 4a). In the PD group ES model fit


increased marginally after prebiotics (p>0.05, Wilcoxon signed-rank test), while this

increase was significant in CO (P=0.049, Wilcoxon signed-rank test, Suppl. Fig. 4a),

204 indicating that the gut microbiome after the diet intervention is more similar to an

- average gut microbiome from the enterosignature model (trained on >5,000 gut
- 206 microbiomes<sup>27</sup>).

The dietary intervention had a strong impact on overall ES composition (Suppl. Fig. 4b), explaining 30% of variance amongst samples (after conditioning out the "household-effect", R<sup>2</sup>=0.30, p<0.001, perMANOVA, Suppl. Fig. 4c). This was



## Suppl. Figure 4 Enterosignatures

A, ES model fit is comparable between groups and most samples have a model fit above 0.75. Note that only the CO group showed an increased model fit after prebiotics (p=0.049,Wilcoxon signed-rank test); B, ES composition along study samples shown as the relative abundance of the respective ES per patient; C, Dissimilarity in ES composition was explained by the dietary intervention (R<sup>2</sup>=0.30, p<0.001, perMANOVA); D, Dissimilarity in ES composition showed no difference between PD and CO neither before nor after prebiotics (unconstrained dbRDA, Bray-Curtis distance). \* = p<0.05

probably driven by an increase in ES-Bifi (Bifidobacterium dominated guild, p<=0.01</li>
in both CO and PD, Wilcoxon signed-rank test), and decrease in ES-Firmi (Firmicutes
dominated guild, p=0.08 and p=0.04 in CO and PD, respectively, Wilcoxon signedrank test) after the prebiotic intervention (Fig. 3b). Note that this effect seemed overall
stronger in PD than CO microbiomes and is potentially related to a higher intake of
Lactulose in this group.

216

# The prebiotic intervention enhanced the bacterial metabolic potential for fatty acid metabolism in PD and CO and strengthened neuroprotective and antioxidative pathways in PD


Given the apparent consolidation of the PD dysbiosis following prebiotics, we sought 220 to ascertain whether the intervention exerted any influence on the functional potential 221 of the microbiome. For this we used key metabolic pathway modules relevant for gut 222 bacterial metabolism from the KEGG database<sup>28</sup>, as well as GBM<sup>29</sup> modules 223 especially relevant for human brain functions. The functional composition of both, 224 general and brain relevant pathways, was again dominated by household effects, 225 which accounted for 42.1% and 49.1% of the total variance. In contrast, differences 226 between PD and CO, explained 7.7% and 8.8% of variance in KEGG modules, while 227 7% and 6% of variance were explained through GBM modules, respectively (all 228 p<0.001, perMANOVA). Interestingly, the dissimilarity for KEGG modules between PD 229 and CO before prebiotics decreased after prebiotics, while GBM differences between 230 PD and CO became more pronounced after prebiotics (perMANOVA conditioned for 231 232 household, KEGG before: R<sup>2</sup>=0.10, p=0.028, after prebiotics: R<sup>2</sup>=0.08, p=0.048, GBM before: R<sup>2</sup>=0.07, p=0.025, after prebiotics: R<sup>2</sup>=0.10, p=0.003). 233

Investigating the modules driving these differences between PD and CO, we find the 234 PD microbiome enriched in bacterial functions related to drug efflux and drug 235 resistance, similar to our findings in 2017<sup>6</sup>. CO microbiomes were instead enriched in 236 genes related to saccharide, polyol, and lipid transport systems (Fig. 3c). PD patients 237 had increased abundances of genes related to butyrate synthesis, and decreased S-238 239 adenosylmethionine (SAM) synthesis (p<0.05, q>0.1, Wilcox rank sum test) compared 240 to CO, but this was normalized after prebiotics (n.s. difference to CO, Suppl. material 1). After the prebiotic intervention, other functions differed between PD and CO, 241 including Dihydroxyphenylacetic acid (DOPAC) Synthesis and GABAII Synthesis 242 (decreased abundance in PD, p<0.05, q<0.1, Suppl. material 1) and Tryptophan 243 degradation (increased abundance in PD, Wilcoxon rank sum text, p<0.05, q>0.1, 244 Suppl. material 1). 245

We next determined bacterial functions changed with the prebiotic diet (before vs. after prebiotics comparisons). In both CO and PD, multiple fatty acid metabolism related genes increased in relative abundance after prebiotics, involved in the synthesis of medium- and long-chain fatty acids (Fig. 3c and 3d).

All rights reserved. No reuse allowed without permission.

#### 250



#### Figure 4, Functional metabolic potential and metabolite levels

A, brain-relevant functional metabolic potential (GBM modules) improves after prebiotics in PD in a potentially neuroprotective manner, e.g. p-cresol synthesis decreased and quinolinic acid degradation increased, both leading to neurotoxic compounds. X- and y-axis corresponds to p-values of Wilcoxon signed-rank test for changes due to the prebiotic intervention of CO (x-axis) and PD (y-axis) patients. B, the relative abundance of bacterial functional GBM modules improved only in PD patients after the prebiotic intervention compared to baseline before prebiotics (upper panel, p<0.05, q<0.1, Wilcoxon signed-rank test). This was also reflected in corresponding urinary metabolites (bottom panel, p>0.05, Wilcoxon signed-rank test). C, urine metabolite composition differed between PD and CO before prebiotics, but normalized after prebiotics (permutation test, before prebiotics:  $R^2$ =0.08, p=0.044; after prebiotics:  $R^2$ =0.05, p=0.36). \* 0 p<0.05, \*\* = p<0.01; D, faecal metabolite profiles before prebiotics were different in SCFA's between PD and CO. After prebiotics these differences are no longer observed, instead amino acid concentrations were different between PD and CO (all q >0.1, Wilcoxon rank sum test); But= butyrate, Isobut= isobutyrate, Prop= propionate.

In addition, 19 KEGG modules related to nucleotide, amino acid, carbohydrate and
lipid metabolism were significantly changed in both PD and CO after prebiotics (Suppl.
material 1). Notably, the prebiotic diet decreased formaldehyde assimilation, which is
identified as increased in the PD dysbiosis <sup>30</sup>.

Compared to baseline values before prebiotics, several alterations in KEGG modules 255 (N=20) were only different in PD patients (but not in CO) after prebiotics, e.g., 256 257 Sulphate-sulphur-assimilation pathway associated genes decreased, genes related to glutathione (GSH), serine synthesis as well as branched chain amino acid transport 258 259 increased (Wilcoxon signed-rank test, Suppl. material 1 and Fig. 3d), the latter matching our metabolomic observations (see below). Notably, several bacterial 260 pathways leading to brain relevant metabolites changed after prebiotics (p<0.05, 261 Wilcoxon signed-rank test, Fig. 4a and 4b). These could have potentially positive 262 implications for PD patients, e.g. the changes in genes related to both the neurotoxic 263 p-cresol and quinolinic acid (decreased synthesis and increased degradation, 264 respectively). Inositol synthesis genes increased, and inositol degradation genes 265 decreased (a neuroprotective metabolite). 266

# 267 Bacteria driving changes in functional potential

To better understand the contribution of taxonomic changes to the observed changes in bacterial pathways, we correlated KEGG and GBM modules to MGS species clusters (partial correlation to correct for the time series). These functional metabolic changes could be correlated to different microbes, that were all previously implicated in PD<sup>4,6</sup> (Suppl. material 2). Fatty acid synthesis (initiation and elongation) and betaoxidation/acyl-CoA-synthesis correlated positively to several *Bifidobacteria* species, but negatively to *Alistipes spp*. and *Barnesiella spp*.. The former species contributes

to the dysbiosis associated to PD, suggesting that an induced depletion of these taxacould benefit PD patients.

277 Several members of *Bifidobacteria* and *Oscillospiraceae* correlated to branched chain amino acid transport pathways (changed only in the PD group in before vs. after 278 prebiotics comparisons), while e.g., Blautia A spp. showed a strong negative 279 correlation. Further, *Eubacterium I spp*. were the strongest sign. positively correlating 280 281 taxa with Sulphate-sulphur-assimilation (Suppl. material 2). Regarding brain-relevant GBM functions, a strong positive correlation was observed for different *Alistipes spp*. 282 283 with inositol degradation as well as with p-cresol-synthesis, again suggesting that a diet-depleted *Alistipes spp.* would be of benefit in PD due to potentially reduced levels 284 of neurotoxic compounds. 285

286

#### 287 PD faecal and urine metabolites profiles normalized with the diet intervention

Faecal metabolites<sup>31</sup> approximate the bacterial metabolism in the gut, while urine metabolites<sup>32</sup> can reflect both human and bacterial metabolism. We therefore analysed both faecal and urine metabolomes (NMR) of our cohort (N=80, coinciding with faecal sample collections). Variance in both urine and faecal metabolites was again mostly driven by differences between households (perMANOVA, R<sup>2</sup>=0.36, p<0.001, and R<sup>2</sup>=0.45, p<0.001; respectively, Suppl. Table 2), but study groups (PD vs. CO) had a sign. different urine metabolites composition (R<sup>2</sup>=0.04, p=0.03).

Testing dissimilarities in urine metabolites for both timepoints separately (conditioning for households) revealed that the PD urinary metabolite profiles after the prebiotic intervention resembled the CO profiles (Fig. 4c). However, no clear causative biological signal was derived from the single metabolite composition to better explain this improvement based on differential abundance testing of all metabolites in urine between PD and CO. Comparing faecal metabolites between PD and CO before and

301	after prebiotics revealed t	hat several faecal SCFA	A normalized after prebioti	cs in the
302	PD group (e.g., Iso-/Buty	rate and Propionate); in	stead, amino acids conce	ntrations
303	differed, such as a decrea	ase in Alanine and Iso-/I	Leucine (Wilcoxon Rank S	sum test,
304	p<0.05, q>0.1, Fig. 4d), or	neurotoxic metabolites (	but p>0.05, Fig. 4b), corres	sponding
305	to the observed changes i	n the gut metabolic funct	tional potential. Although li	mited by
306	our cohort size, this highli	ghts a plausible biologica	al relation and potentially i	mportant
307	result	for	PD	patients.

308

309

#### 310 **DISCUSSION**

# 311 Key results- Beneficial effects of the prebiotic diet for PD patients

The short-term prebiotic diet intervention was safe and well tolerated in all subjects 312 (mild bloating was the only complain) and resulted in increased SCFA concentrations 313 and improved gastro-intestinal symptoms in PD. We observed a trend towards 314 reduced disease severity (UPDRSIII), which was inversely correlated with SCFA 315 concentrations, indicating the importance of SCFA's for gastro-intestinal functioning 316 and possibly also motor symptoms in PD. Interestingly, in a recent study of faecal 317 microbiota transplant<sup>33</sup>, the improvement in motor symptoms became pronounced 318 between the sixth and twelfth month after the transplant, suggesting that the effects of 319 a dietary intervention might also occur at a later point than assessed here. 320

We observed several gut microbes that were sign. different before and after the 321 intervention between PD and CO metagenomes, and these coincided with several 322 well-known "dysbiotic" PD gut microbes. However, on a functional and metabolic level, 323 the prebiotic diet appeared to remove most of the aberrations observed between PD 324 and CO patients, presumably improving gut microbial metabolism in PD patients: 325 Apart from normalized SCFA concentrations in the faecal metabolite profile, we also 326 327 found decreased branched chain amino acids (BCAA), potentially harmful for neurons by oxidative stress<sup>34</sup>, mitochondrial dysfunction<sup>34</sup>, and a decrease in dopamine 328 synthesis<sup>35</sup>, while presumably neurotoxic compounds associated with PD<sup>36,37</sup> were 329 reduced in the urine metabolites after prebiotics (the aromatic amino acid p-cresol-330 sulfate, and the tryptophan/kynurenine downstream metabolite quinolinic acid). This 331 coincided with changes in corresponding bacterial pathways derived from the 332 333 metagenome. The prebiotic intervention seemed to restore a normal metabolite profile

in general, as PD urinary metabolomic profiles were no longer distinct from CO afterthe prebiotic intervention.

Our analyses identified and had to be statistically corrected for a prevailing "household effect". The importance of family shared microbes (possibly arising from social interactions, shared environments or diet) has been described before<sup>38,39</sup>, but the scale accounting for >36% (mean 44%) of explained variance at all data levels (Suppl. Table 2) was surprising to us.

### 341 SCFAs at the Blood-Brain-Barrier

342 SCFAs, increased due to the prebiotic intervention in our cohort, have a range of presumed beneficial effects on gut- and blood-brain-barrier (BBB) integrity<sup>9,40</sup>. 343 Translocating from the intestines to the systemic circulation, SCFA can reduce 344 neuroinflammation<sup>41</sup> and contribute to microglia maturation<sup>42</sup> in murine models. 345 Propionate, enriched in PD patients after prebiotics, has anti-inflammatory and BBB 346 permeability-reducing effects in human brain endothelial cells<sup>43</sup>. Dietary fibre and 347 SCFA can suppress intestinal inflammation, thereby improving the gut barrier function 348 based on animal and cell culture studies <sup>44,45,46</sup>. In addition to the observed changes 349 in SCFA concentrations, we identified enriched bacterial pathways for fatty acid 350 metabolism (middle-chain fatty acids, MCFAs, and long-chain fatty acids, LCFAs). 351 MCFAs have been shown to have beneficial effects, particularly on metabolic features 352 and insulin sensitivity<sup>47</sup>, and LCFAs like palmitic acid (pathways enriched in our study), 353 can lead to enhanced IqA antibody production *in vitro* and in mice<sup>48</sup>, contributing to 354 host defence against pathogenic microorganisms. 355

## 356 **PD microbiome is not restored through prebiotics**

To date, only few studies investigated the effects of dietary interventions on PD gut microbiome dysbiosis, focusing on constipation<sup>49,50</sup> and/or pharmacokinetics<sup>49</sup>. The

effects of dietary mixed fibres were investigated in a cohort<sup>56</sup> of n=10 PD subjects over 10 days resulting in increased plasma SCFA, gut integrity markers and reduction in potentially pathogenic family (*Enterobacter*), while potentially SCFA-producing species (*Bifidobacterium*, *Faecalibacterium*) were increased, in accordance with our results after a 1-month intervention. With the inclusion of a control group, we could also characterize and monitor the PD-associated dysbiosis, corroborating our earlier work<sup>4,6</sup>.

The PD dysbiosis persisted during the diet intervention. Whether extended prebiotic 366 367 use could restore the PD microbiome in the long-term, or if other, as-yet-unknown host-microbe or microbe-microbe mechanisms are responsible, remains a subject for 368 further research. The microbiome is highly individual (or family) specific<sup>38,39</sup> and 369 distinct microbial communities might show divergent responses to prebiotics, 370 indicating a hierarchical specificity towards gut microbes<sup>51</sup>, potentially limited by 371 physico-chemical fibre characteristics. These mechanisms might be strain specific. 372 Dysbiosis associated taxa (e.g., Akkermansia) in PD patients might stem from specific 373 strains, which are particularly successful in outcompeting other microbiome taxa but 374 with detrimental effects for the host. The removal of a persistent (dysbiosis associated) 375 member of the microbiota might require much stronger remedies than a prebiotic, as 376 most bacterial strains persist in the gut microbiome for extended periods<sup>39</sup>. Other 377 factors that favour dysbiotic taxa in PD patients include constipation and increased 378 transit time, as discussed in<sup>4</sup>. Although it is tempting to speculate, that the PD 379 microbiota is less adaptable and remains therefore trapped in a dysfunctional state, 380 we cannot exclude that the persistent dysbiosis might be a less favourable effect of 381 the SCFA-enhancing diet in PD. 382

#### All rights reserved. No reuse allowed without permission.

#### Alterations in bacterial functional capacity with potential pathophysiological 383 implications for PD 384

Following prebiotic intervention, alterations in gene abundance were identified in 385 multiple bacterial metabolic pathways, particularly within the PD cohort. These findings 386 offer a potential pathophysiological relevance to PD. This included a normalized SAM 387 synthesis, enhanced GSH metabolism, decreased DOPAC synthesis, and an 388 increased Tryptophan degradation along with the above-mentioned reductions in 389 pathways resulting in neurotoxic metabolites (p-cresol sulphate and guinolinic acid) 390 391 and increase in a pathway resulting in the neuroprotective metabolite myo-inositol.

SAM, an endogenous amino acid metabolite involved in the methylation and trans-392 sulfuration processes critically modulates autophagy<sup>52</sup>, a process also relevant for PD, 393 but excessive SAM on the other hand has been shown to cause PD like symptoms in 394 rats<sup>53</sup>. It has been suggested that PD severity is related to a disturbed host-trans-395 sulphuration, a pathway central to antioxidant response, along with an increased 396 bacterial Sulphur-metabolism<sup>76</sup>, related potentially to PD medication<sup>54</sup>. GSH (a SAM 397 derived metabolite) is involved in neuro-immune and neuro-oxidative processes and 398 in the regulation of cell death. Reduced GSH levels also is a key finding in PD brain 399 tissue<sup>55</sup>, associated with mitochondrial dysfunction constituting a critical factor in the 400 neuroinflammatory and -degenerative processes in PD<sup>56</sup>. The major dopamine 401 metabolite, dihydroxyphenylacetic (DOPAC), seems to play a role in PD 402 pathophysiology associated cell death<sup>57</sup> and mitochondrial inhibition. Prebiotically 403 decreased bacterial DOPAC concentrations in parallel with elevated antioxidative 404 GSH concentrations in the gut lumen could in turn be advantageous for the human 405 host with PD. However, it remains to be seen whether the aforementioned changes in 406

407 bacterial metabolism or respective metabolite changes within the gut lumen will reach

the human host in a manner that beneficially influences the PD process.

## 409 The therapeutic potential for Bifidobacteria in PD

The prebiotic intervention led to a substantial increase in *Bifidobacteria*. Bifidobacteria were among the taxa consistently increased in PD patients<sup>4,58</sup>, albeit several studies<sup>59,60</sup> controlled for laxatives such as the *Bifido*-genic Lactulose used here.

These *Bifidobacteria* were most likely already colonizing the host's gut and might therefore be more desirable for the PD patient, as seeding the gut microbiome with newly colonizing *Bifidobacteria* (or any other probiotic) could inadvertently negatively impact the gut microbiome, e.g. elicit an immune response to so-far-unknown taxa and/or disrupt the established and stabilized microbial ecosystem through the new strains. Prebiotics may represent a more suitable option for chronic conditions such as PD than probiotics, because of their longer-lasting effects<sup>58,59</sup>.

Bifidobacteria have the potential to benefit the PD patient and they are sometimes 420 used as *Psychobiotics*<sup>60</sup> (a subclass of probiotics), given their ability to stimulate 421 neurotransmitters, SCFA, anti-inflammatory cytokines, production of y-aminobutyric 422 acid (GABA) or tryptophan <sup>61,62</sup> or enteroendocrine hormones with potentially brain-423 protective functions. However, Bifidobacteria could also be harmful, as their 424 metabolism of tryptophan can produce potentially harmful metabolites (i.e., the 425 neurotoxic quinolinic acid<sup>63</sup>) and certain *Bifidobacteria* strains can *in vitro* metabolize 426 L-Dopa via a deamination<sup>64</sup>, potentially interfering with standard PD pharmacotherapy. 427 Thus, despite many potential benefits that *Bifidobacteria* could provide, the actual 428 species and strains already residing in a microbiome should be assessed before 429 manipulating their abundances through prebiotic interventions. 430

431 Limitations

Due to the limited number of subjects involved in this pilot study, the resulting data may be subject to bias and therefore require further corroboration. Lactulose was prescribed to PD patients as a basic medication to treat constipation at a dosage exceeding that used in the control group i.e., prebiotic dosage given for reasons of comparability. However, given our intention to investigate potential disease-modifying strategies that are particularly focused on PD patients, this approach may be deemed justifiable.

#### 439 CONCLUSION

440 A systematic investigation of metagenomics and metabolomics in both faecal and urine samples demonstrated that a SCFA-promoting diet modulated the metabolism 441 of the intestinal microbiota in PD patients, along with improved gastro-intestinal 442 symptoms. Hence, the potential of a microbiota-directed prebiotic intervention as a 443 modifying therapeutic approach in PD appears promising. To safely exploit the 444 445 therapeutic potential of Bifidobacteria in PD, we suggest using strain resolved metagenomics to guide prebiotic regimes to control for potentially harmful effects 446 (such as L-Dopa deamination). It remains to be determined whether the dysbiosis 447 associated with PD can be restored with longer-term prebiotic interventions or may 448 require a probiotic approach or a (faecal) microbiome transfer. Larger placebo-449 controlled trials with longer-lasting dietary interventions including different types of 450 fibres and probiotic interventions are required and justified given the beneficial 451 metabolic changes observed in our data. 452

453

#### 454 **METHODS**

#### 455 **Study design and participants**

This prospective controlled clinical pilot study was approved by the local ethics committee of the University of Bonn, Germany, and all participants gave written informed consent (internal ethics vote 145/17).

The study was registered in the German Clinical Trials Register (DRKS under the 459 460 number DRKS00034528). Inclusion criteria were: (1) idiopathic PD (mild to moderately advanced, i.e., Hoehn and Yahr 1-2) with (2) stable medication within the previous 461 462 three months, and (3) willingness for their healthy non-PD spouses to participate; (4) both at ages  $\leq$  75 years. Exclusion criteria were (1) atypical parkinsonism; (2) PD 463 patients with deep brain stimulation or continuous intestinal levodopa infusion; (3) 464 chronic and inflammatory gastrointestinal diseases including severe chronic 465 constipation; (4) the use of laxatives, antibiotics, or immunosuppressive agents in the 466 past three months (note that n=1 PD took 1 day of antibiotics 4 weeks before study); 467 (5) lactose intolerance; and (6) veganism. Participating PD patients were recruited 468 from the Department of Neurology, University of Bonn, Germany, and underwent the 469 dietary intervention together with their healthy spouses. The control group was 470 selected to ensure a certain degree of standardisation and comparability with regard 471 to the dietary recommendations provided throughout the course of the study. 472 Furthermore, it was hypothesised that habitual diets would prove more comparable to 473 those of age-matched healthy controls, thus enhancing the reliability of the baseline 474 conditions. The recruitment of participants was conducted between October 2017 and 475 July 2019, with the relevant study data collected concurrently. N=11 PD patients and 476 their N=11 healthy spouses (control group, CO) were included in the study. One couple 477

478 (1 PD, 1 CO) withdrew from the study before the final visit for reasons not related to479 the study.

PD was clinically diagnosed according to the UK Brain Bank criteria. Disease severity 480 was measured using the Movement Disorders Society Unified Parkinson's Disease 481 Rating Scale (MDS UPDRS) part III. Gastrointestinal symptoms and constipation 482 presence were evaluated through a Gastrointestinal Symptom Rating Scale (GSRS 483 <sup>65</sup>, selected items: borborygmus, abdominal distension, increased flatus, decreased 484 passage of stools, increased passage of stools, loose stools, hard stools, urgent need 485 486 for defecation and feeling of incomplete evacuation, rated 0-3 based on intensity, frequency, duration, or social impact) and a post-prebiotic interview for adverse 487 effects. 488

### 489 **Dietary intervention**

All participants agreed to follow a recommended diet, a combination of nutrients rich 490 in fibres, fruits, and vegetables for 4 weeks: a combination of i) 2 apples/10 apple rings 491 a day (rich in pectin, a polysaccharidic prebiotic) and ii) 5 portions per week (portion= 492 the size of the own hand) of foods rich in resistant starch, lignin, and anthocyanins 493 (lentils, potatoes, green beans, onions, oat bran, lettuce, olive oil, and bananas as well 494 as strawberries). PD patients were taking a prebiotic Lactulose syrup to treat 495 constipation as a basic medication and the spouses thus were ingesting Lactulose in 496 a prebiotic dosage. Lactulose, a non-digestible synthetic disaccharide, is used for 497 different purposes, such as a prebiotic, for constipation and hepatic encephalopathy 498 treatment (ranging from 10g to 100g respectively). PD patients took 2x15 mL (2x10 g) 499 daily for treatment of constipation, while controls took 1x15 mL (1x10 g, i.e., prebiotic 500 dosage). Lactulose is anaerobically fermented in the colon by microbiota, enhancing 501 *Bifidobacteria*, *Lactobacillus* (and SCFA<sup>66,67</sup>). Dietary baseline information was 502

assessed with a questionnaire (Suppl. material 3). Diet compliance was verified 503 through self-maintained food logs over the 4 weeks, reviewed after completion of the 504 study (n=7 representative diet days per subject, i.e., n=5 weekdays and n=2 weekend 505 days across the 4 weeks). Diet diaries were analysed using the Nutritics dietary 506 analysis software (Nutritics Ltd), based on the German Food Composition Database 507 available within Nutritics. To establish a comparable and scalable measure for 508 509 assessing dietary adherence, we focused on measuring the consumption of raw apples, as they are easily quantifiable, as well as total fibre intake. It should be noted, 510 511 however, that apple/fibre consumption alone does not necessarily indicate full adherence to our recommendations. Due to the nature of our recommendation as a 512 portion (resembling the size of the own hand) and because we did not systematically 513 quantify dietary habits over a longer period before intervention, application of absolute 514 values of other nutrients was considered inappropriate. The food score was calculated 515 as following: the consumption of raw apples based on our given recommendations (2 516 Apples= 365 g/d or 10 Apple rings dried = 65 g/d) was considered 100% adherent. 517 Then the fraction of the participants' diet days with an apple consumption below the 518 mean apple consumption of all participants was computed (mean=70%/d of our 519 recommendation). A fraction of more than 0.75 days was considered as less adherent. 520 Additionally, dietary analysis including estimating the average fibre intake of every 521 representative day was calculated and used for basic statistical testing (see below), 522 using the Nutritics dietary analysis software. 523

524 Sample collection

525 Urinary and faecal samples were non-invasively collected at baseline and 4 weeks 526 after diet. Faecal samples were put in a specimen collector (Sarstedt) and stored in a 527 plastic bag under anaerobic conditions (Anaerocult® P, Merck Millipore). Participants were advised to collect samples the latest the evening prior to or at the day of the study visit. All samples were cooled in a refrigerator (5-7 °C) at the patients' home and transported to the study site with a cool pack. Samples were immediately stored at -80°C upon arrival at the study site. Additionally, routine laboratory parameters were assessed at baseline and 4 weeks after diet (focusing on serum sodium and potassium levels as safety measures due to the ingestion of Lactulose syrup).

#### 534 Outcome

535 Primary: i) modification of SCFA in faeces, ii) changes in gut microbial composition

including key species for SCFA production, and iii) changes in bacterial metabolism

537 based on bacterial genomes and metabolomics analysis in urine and faeces.

538 Secondary: i) changes in motor symptoms (UPDRSIII), ii) modification of gastro-539 intestinal symptoms (modified GSRS, stool frequency, side effects).

# 540 Faecal DNA Extraction and sample preparation

DNA extraction was performed with the Maxwell® RSC PureFood GMO and 541 Authentication Kit (Cat. #AS1600) according to the manufacturer's recommendations. 542 In brief, 200 mg of faeces were placed into a 2 mL microcentrifuge tube and 1 mL of 543 CTAB Buffer was added. Samples were heated at 95°C for 5 minutes and allowed to 544 cool down for 2 minutes. Manually homogenisation was performed with bead beating 545 in the 2 mL Lysing Matrix E tubes (containing 1.4 ceramic spheres, 0.1 silica spheres, 546 and one 4 mm glass bead) using a Homogenizer (FastPrep, Setting/Speed 6.0, 3 547 times for 1.0 minute). Samples were then mixed with 40 µl of proteinase K and 20 µl 548 of RNase A and incubated at 70°C for 10 minutes. Cartrides were prepared according 549 to the manufacturer's recommendations (300 µl lysis buffer). The Maxwell RSC was 550 run with the PureFood Protocol, automatically purifying and eluting DNA in 100µl. 551

552 Sequencing

Genomic DNA was normalised to 5 ng/µl with EB (10mM Tris-HCl). A miniaturised 553 reaction was set up using the Illumina Nextera DNA Flex Library Prep Kit (Illumina 554 Catalogue No 20018704). 0.5 µl Tagmentation Buffer 1 (TB1) was mixed with 0.5 µl 555 Bead-Linked Transposomes (BLT) and 4.0 µl PCR grade water in a master mix and 5 556 µl added to a chilled 96 well plate. 2 µl of normalised DNA (10 ng total) was pipette 557 mixed with the 5 µl of the tagmentation mix and heated to 55 °C for 15 minutes in a 558 PCR block. A PCR master mix was made up using 4 ul kapa2G buffer, 0.4 µl dNTP's, 559 0.08 µl Polymerase and 4.52 µl PCR grade water, contained in the Kap2G Robust 560 561 PCR kit (Sigma Catalogue No. KK5005) per sample and 9 µl added to each well need to be used in a 96-well plate. 2 µl of each P7 and P5 of Nextera XT Index Kit v2 index 562 primers (Illumina Catalogue No. FC-131-2001 to 2004) were added to each well. 563 Finally, the 7 µl of Tagmentation mix was added and mixed. The PCR was run with 564 72°C for 3 minutes, 95°C for 1 minute, 14 cycles of 95°C for 10s, 55°C for 20s and 565 72°C for 3 minutes. Following the PCR reaction, the libraries were quantified using the 566 Quant-iT dsDNA Assay Kit, high sensitivity kit (Catalogue No. 10164582) and run on 567 a FLUOstar Optima plate reader. Libraries were pooled following quantification in 568 equal quantities. The final pool was double-SPRI size selected between 0.5 and 0.7X 569 bead volumes using KAPA Pure Beads (Roche Catalogue No. 07983298001) and 570 quantified on a Qubit 3.0 instrument and run on a D5000 ScreenTape (Agilent 571 Catalogue No. 5067- 5588 & 5067- 5589) using the Agilent Tapestation 4200 to 572 calculate the final library pool molarity. 573

574 Samples were sent to Novogene (Novogene (UK) Company Limited, 25 Cambridge 575 Science Park, Milton Road, Cambridge, CB4 0FW, United Kingdom) to be run along 576 with sample names and index combinations used. Faecal samples were shotgun 577 sequenced (paired end) using an Illumina Novaseq 6000 at Novogene. Demultiplexed

578 fastq's were returned on a hard drive, and further analyzed with the Matafiler 579 Pipeline<sup>39</sup>.

#### 580 Targeted SCFA measurements in faeces

Frozen aliquots of raw faeces were sent to an external laboratory (GANZIMMUN 581 Diagnostics GmbH, Hans-Böckler-Str. 109, 55128 Mainz, Germany) to measure 582 SCFA levels via GC-MS (GC; Perkin Elmer Clarus 680, MS: Perkin Elmer Clarus 583 584 SQ8). In brief, 1 g of raw faeces was suspended and homogenized in 26% NaClsolution (ACROS - 387640025). Then 900 mL 6M HCl were added for stabilization. 3 585 586 mL of the former were transferred into a plastic tube together with 30 µL of Istd-solution (100 µL 2-ethylbutyric acid in 9.9 mL 0.6 M HCI-solution). Samples were thoroughly 587 mixed and 50 µl, placed into a Wheaton-Vial, and closed with a crimp-cap. Calibration 588 standards of the respective SCFA were similarly prepared in 26% NaCl, stabilized with 589 6 M HCL, and treated analogously as the faecal samples. Then levels of SCFA were 590 measured (Headspace-System: Perkin Elmer TurboMatrix 40, Column: Phenomenex 591 Zebron ZB-FFAP, 30 m length, 0.25 mm ID, 0.25 µm width, gas: Helium, 80 kPa, 592 injection-volume: 1 µL, temperature-program: 2 min at 45 °C, heating (15°C/min) to 593 reach 250°C, heat 250°C for a duration of 10 min, Headspace-temperatures: Vial-594 Oven 60 °C, transfer line 110 °C, injection-pin 95 °C). Data was sent electronically 595 with SCFA concentrations given in µmol per 1 g faeces. 596

597

## 598 Non-targeted metabolomics analysis in urine and faeces

599 Nuclear magnetic resonance (NMR) spectroscopy was used for non-targeted 600 metabolomics. A detailed description of the metabolomics method including urine 601 sample preparation, NMR analysis and data processing is outlined in Heinzmann et 602  $al^{32}$ . In brief, 150 µL of urine is mixed with 50 µL PO<sub>4</sub>-buffer (100% D<sub>2</sub>O) and 10 µL 603 4.5 M KF in D<sub>2</sub>O. To extract aqueous faecal metabolites, we homogenized 50 mg

faeces in 1 mL H<sub>2</sub>O using ceramic beads (NucleoSpin, Macherey–Nagel, Dueren, 604 Germany) and a TissueLyser (Qiagen, Hilden, Germany) mixing for 3 x 20 sec at 4500 605 rpm with a 10 sec cooling break (<  $0^{\circ}$ C). Subsequently, the homogenate was 606 centrifuged (13.000 rpm for 10 mins at 4°C), the supernatant evaporated with a 607 SpeedVac, the dried extract reconstituted in 150 µL H<sub>2</sub>O and mixed with 50 µL NMR 608 buffer and 10 µL 4.5 M KF. Samples were immediately submitted to NMR analysis and 609 the same workflow protocols were used for urine and faecal extracts<sup>32</sup>. For metabolite 610 identification, we analyzed the quality control sample (i.e., a mixture of all samples in 611 612 the study) as a representative sample of urine and faecal water extract respectively with a series of 2-dimensional NMR analyses as specified in<sup>68</sup>. Data were imported 613 into Matlab software R2011b (Mathworks, Natick, MA, USA) and the water region 614 removed, and spectra normalized<sup>69</sup>. Relative quantification of metabolites was done 615 using the peak height of selected peaks, as identified by a peak picking algorithm<sup>70</sup>. 616 As the urine metabolites were commonly characterized by multiple peaks, we chose 617 the best representative peaks for data reduction prior to statistical testing. 618

### 619 ELISA (faecal Calprotectin and Alpha-1-Antitrypsin

620

Quantitative determination of calprotectin and alpha1-antitrypsin in stool each was
performed with an enzyme linked immunoassay from Immundiagnostik AG
(Stubenwald-Allee 8a, 64625 Bensheim, Germany; calprotectin: IDK® Calprotectin
ELISA, K 6927, K 6927.20, MRP (8/14, S100A8/A9); alpha1-antitrypsin: IDK® α1antitrypsin ELISA, K 6760) following the manufacturer's instructions.

#### 626 Genome reconstruction, taxonomic and functional profiling of metagenomes

627 MATAFILER <sup>39,71</sup> (<u>https://github.com/hildebra/MATAF3)</u> was used to process raw 628 reads, assemble metagenomes, reconstruct metagenomics assembled genomes

(MAGs) and dereplicate these to metagenomic species (MGS). Briefly, raw shotgun
 metagenomes were quality filtered using sdm v1.63 with default parameters<sup>72</sup>.

Kraken2<sup>73</sup> was used to remove human reads. Host-filtered metagenome reads, were assembled using MEGAHIT v 1.2.9<sup>74</sup> and reads were backmapped onto the assembly using Bowtie2 v2.3.4.1<sup>75</sup>, genes predicted with Prodigal v2.6.1 with parameters "-p meta" and a gene catalogue clustered at 95% nt identity using MMseqs2<sup>76</sup>. Matrix operations on the gene catalog were carried out using rtk2<sup>77</sup>.

MAGs were calculated using SemiBin2<sup>78</sup>, their completeness and contamination estimated using checkM2<sup>79</sup>. Using a combination of SemiBin2 MAGs and canopy clusters<sup>80</sup> (https://github.com/hildebra/canopy2), high-quality reference genomes (>80% completeness, <5% contamination) were dereplicated into metagenomic species (MGSs) using clusterMAGs (<u>https://github.com/hildebra/clusterMAGs</u>) in MATAFILER. Abundances of MGS in different samples were estimated based on conserved marker genes and their median abundances within the gene catalog.

### 643 Enterosignature calculation

The reapplication Enterosignatures (ES) generated of were at 644 https://enterosignatures.guadram.ac.uk/. The Genus abundance table was fitted to the 645 five Enterosignatures model<sup>27</sup> and taxa names were matched between the abundance 646 table (H) and the five Enterosignatures W matrix, which gives the weight of each taxon 647 in each signature. The W matrix and H have been modified so taxa names and orders 648 in each match. ES are a set of five signatures that represent common microbial guilds 649 complementary in their metabolism and found in all gut samples. The ES model allows 650 to define a normal/homeostatic microbiome, i.e., a low model fit =< 0.4 could be 651 suggestive of a microbiome in an atypical state (or at least in a state that was not well 652 represented amongst the >5,000 gut microbiomes the model was originally learnt 653

from). Brain related metabolic functional potential was assessed with a previously
 published database of manually curated gut-brain modules<sup>81</sup> (GBMs, with each
 corresponding to a single neuroactive compound production or degradation process).

### 657 Statistical analyses

Statistical analysis was conducted in R 4.1.3. Alpha-diversity and Beta-diversity 658 indices and compositional analyses were calculated using the R-packages rtk<sup>77</sup>, 659 phyloseq<sup>82</sup>, microbiome<sup>83</sup>, and vegan<sup>84</sup>, and data was visualized with ggplot2 and 660 custom R scripts. For Alpha-diversity measures i.e., indices of diversity and evenness 661 662 (Shannon, Simpson) and richness (Observed, Chao1, and ACE), sample count matrices were rarefied to 90% of the minimal sample sum to ensure even sampling 663 depth. For Beta-diversity i.e., the quantification of sample dissimilarity (between PD 664 and CO or between before and after prebiotics based on Bray-Curtis or Euclidean 665 distance, see below) and taxonomic composition, taxa count matrices were 666 normalized by dividing each feature by the respective total sample sum (TSS). 667

For univariate tests, features from the abundance matrix were removed that were 668 present in less than four samples or had less than 0.001% relative abundance. 669 Significance between PD and CO was tested with a paired samples Wilcoxon rank-670 sum (Wilcoxon signed-rank test, function "wilcox.test(..., paired=TRUE)") test between 671 couples for each time point separately (PD vs. CO before and PD vs. CO after 672 prebiotics) followed by a multiple testing correction (Benjamini-Hochberg), to account 673 for the "family effect". For within-patient comparisons, a Wilcoxon signed-rank test (see 674 above) was performed on all data (before prebiotics vs. after prebiotics), then multiple 675 testing corrected (Benjamini-Hochberg). Post-hoc testing was performed using a 676 Wilcoxon signed-rank test (PD before vs. PD after and CO before vs. CO after). All P-677 values were corrected for multiple testing using the Benjamini-Hochberg false 678

discovery rate<sup>85</sup> (referred to as q- value) using the function "p.adjust". Differences in 679 categorial metadata between PD and CO were tested with a Fisher's exact test as 680 implemented in base R (function "fisher.test"). For all univariate tests, a p-value <0.05 681 and a q-value <0.1 were considered statistically significant. Effect sizes were 682 calculated using the R-package coin<sup>86</sup> and rstatix, using the function "wilcox effsize" 683 and "coin::wilcoxsign test". The effect size r varies from 0 to close to 1, and we 684 considered 0.10 - < 0.3 (small effect), 0.30 - < 0.5 (moderate effect) and ≥0.5 (large 685 effect). 686

687 For estimation of dissimilarity between study variables we used (un)constrained and conditioned distance-based redundancy analysis (dbRDA, function "dbrda" in 688 vegan<sup>84</sup>). As this function does not allow missing data values, we imputed NAs in 689 metadata with the mean value of the respective variable (this was the case for n=3 690 GSRS and n=1 stool frequency values missing). Estimation of dissimilarity was based 691 on Bray-Curtis distance for taxonomic and function tables (composition of TSS 692 normalized data) or based on Euclidean distance for faecal SCFA, faecal and urine 693 metabolomics on log-transformed data (log x+1). 694

A permANOVA (function "adonis2" in vegan) was used to test the significance of the 695 constraints in the conditioned dbRDA distances. As the household effect had a major 696 impact on data variability (see also results section), we blocked the perMANOVA test 697 for the variable household (i.e., the pairs PD + healthy spouses) with the function 698 "setBlocks" in permute<sup>87</sup> and tested the dissimilarity either for the total data or the 699 different timepoints separately. Dissimilarity matrices were then associated with 700 different variables (study group, time point, metabolites, taxa) with the function "envfit" 701 (with a permutation test as implemented in vegan). 702

For composition plots, taxa were summarized into a higher phylogenetic level (i.e.,

*Genus* level) and rare taxa were combined (with the function "microbiome::aggregate\_taxa" or "microbiome::aggregate\_rare", respectively, as

<sup>706</sup> implemented in microbiome<sup>83</sup>/phyloseq<sup>82</sup>).

707 Partial correlation analyses between taxa and KEGG/GBM modules were conducted

<sup>708</sup> with ppcor<sup>88</sup> with spearman correlation corrected for autocorrelation (with the function

<sup>709</sup> "pcor.test" the pairwise partial correlations between two variables (x, y) can be

controlled for a third variable (z, the individual participant to avoid autocorrelation))

and the correlation matrix was visualized with corrplot<sup>89</sup>.

# 712 Code availability

- The underlying code for this study is available in GitHub and can be accessed via this
- 714 link https://github.com/PDMicro/PDD-scripts.

# 715 Data availability

- The metagenomic sequencing data generated and/ analysed during the current study
- is available in the European Nucleotide Archive, ENA repository, PRJEB57228.
- Further data types are available upon request from the corresponding authors.
- 719

# 720 **References**

- 721
- Collins, S. M. & Bercik, P. The Relationship Between Intestinal Microbiota and the Central Nervous System in Normal Gastrointestinal Function and Disease. *Gastroenterology* **136**, 2003–2014 (2009).
- Spielman, L. J., Gibson, D. L. & Klegeris, A. Unhealthy gut, unhealthy brain: The role of the intestinal microbiota in neurodegenerative diseases. *Neurochem Int* **120**, 149–163 (2018).
- 7283.Bedarf, J. R., Hildebrand, F., Goeser, F., Bork, P. & Wüllner, U. Das729Darmmikrobiom bei der Parkinson-Krankheit. Nervenarzt 90, 160–166 (2019).
- 7304.Romano, S. *et al.* Meta-analysis of the Parkinson's disease gut microbiome731suggests alterations linked to intestinal inflammation. *NPJ Parkinsons Dis* **7**, 27732(2021).

5. Boertien, J. M., Pereira, P. A. B., Aho, V. T. E. & Scheperjans, F. Increasing
Comparability and Utility of Gut Microbiome Studies in Parkinson's Disease: A
Systematic Review. *J Parkinsons Dis* 9, S297–S312 (2019).

- All rights reserved. No reuse allowed without permission.
- Bedarf, J. R. *et al.* Functional implications of microbial and viral gut metagenome
  changes in early stage L-DOPA-naïve Parkinson's disease patients. *Genome Med* 9, (2017).
- 739 7. Collins, S. M., Surette, M. & Bercik, P. The interplay between the intestinal 740 microbiota and the brain. *Nat Rev Microbiol* **10**, 735–742 (2012).
- 8. Braniste, V. *et al.* The gut microbiota influences blood-brain barrier permeability in mice. *Sci Transl Med* **6**, (2014).
- Parker, A., Fonseca, S. & Carding, S. R. Gut microbes and metabolites as
  modulators of blood-brain barrier integrity and brain health. *Gut Microbes* 11, 135–157 (2020).
- Holmes, Z. C. *et al.* Microbiota responses to different prebiotics are conserved within individuals and associated with habitual fiber intake. *Microbiome* **10**, 114 (2022).
- Vijay, N. & Morris, M. Role of Monocarboxylate Transporters in Drug Delivery to
   the Brain. *Curr Pharm Des* 20, 1487–1498 (2014).
- Dalile, B., Van Oudenhove, L., Vervliet, B. & Verbeke, K. The role of short-chain fatty acids in microbiota–gut–brain communication. *Nat Rev Gastroenterol Hepatol* 16, 461–478 (2019).
- Paiva, I. *et al.* Sodium butyrate rescues dopaminergic cells from alpha synuclein-induced transcriptional deregulation and DNA damage. *Hum Mol Genet* 26, 2231–2246 (2017).
- 14. St. Laurent, R., O'Brien, L. M. & Ahmad, S. T. Sodium butyrate improves
  locomotor impairment and early mortality in a rotenone-induced Drosophila
  model of Parkinson's disease. *Neuroscience* 246, 382–390 (2013).
- Matt, S. M. *et al.* Butyrate and Dietary Soluble Fiber Improve Neuroinflammation
   Associated With Aging in Mice. *Front Immunol* 9, (2018).
- 762 16. Sampson, T. R. *et al.* Gut Microbiota Regulate Motor Deficits and
  763 Neuroinflammation in a Model of Parkinson's Disease. *Cell* 167, 1469-1480.e12
  764 (2016).
- Aho, V. T. E. *et al.* Relationships of gut microbiota, short-chain fatty acids,
  inflammation, and the gut barrier in Parkinson's disease. *Mol Neurodegener* 16,
  6 (2021).
- 18. Unger, M. M. *et al.* Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls. *Parkinsonism Relat Disord* 32, 66–72 (2016).
- 19. Chen, S.-J. *et al.* Association of Fecal and Plasma Levels of Short-Chain Fatty
  Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson
  Disease. *Neurology* 98, (2022).
- Gao, X., Cassidy, A., Schwarzschild, M. A., Rimm, E. B. & Ascherio, A. Habitual
  intake of dietary flavonoids and risk of Parkinson disease. *Neurology* **78**, 1138–
  1145 (2012).
- Maraki, M. I. *et al.* Mediterranean diet adherence is related to reduced probability
   of prodromal Parkinson's disease. *Movement Disorders* 34, 48–57 (2019).
- Mischley, L. K., Lau, R. C. & Bennett, R. D. Role of Diet and Nutritional Supplements in Parkinson's Disease Progression. *Oxid Med Cell Longev* 2017, 1–9 (2017).
- Mattson, M. P. Interventions that Improve Body and Brain Bioenergetics for
  Parkinson's Disease Risk Reduction and Therapy. *J Parkinsons Dis* 4, 1–13
  (2014).

- 24. Gilbert, J. A. et al. Current understanding of the human microbiome. Nat Med 785 **24**, 392–400 (2018). 786 David, L. A. et al. Diet rapidly and reproducibly alters the human gut microbiome. 25. 787 *Nature* **505**, 559–563 (2014). 788 Gose, M., Krems, C., Heuer, T. & Hoffmann, I. Trends in food consumption and 789 26. nutrient intake in Germany between 2006 and 2012: results of the German 790 National Nutrition Monitoring (NEMONIT). British Journal of Nutrition 115, 1498-791 792 1507 (2016). 27. Frioux, C. et al. Enterosignatures define common bacterial guilds in the human 793 gut microbiome. Cell Host Microbe 31, 1111-1125.e6 (2023). 794 Kanehisa, M. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic 795 28. Acids Res 28, 27-30 (2000). 796 797 29. Valles-Colomer, M. et al. The neuroactive potential of the human gut microbiota 798 in guality of life and depression. Nat Microbiol 4, 623-632 (2019). 799 30. Rosario, D. et al. Systematic analysis of gut microbiome reveals the role of bacterial folate and homocysteine metabolism in Parkinson's disease. Cell Rep 800 801 **34**, 108807 (2021). 31. Zierer, J. et al. The fecal metabolome as a functional readout of the gut 802 microbiome. Nat Genet 50, 790-795 (2018). 803 32. Heinzmann, S. S., Waldenberger, M., Peters, A. & Schmitt-Kopplin, P. Cluster 804 Analysis Statistical Spectroscopy for the Identification of Metabolites in 1H NMR 805 Metabolomics. Metabolites 12, 992 (2022). 806 Bruggeman, A. et al. Safety and efficacy of faecal microbiota transplantation in 33. 807 patients with mild to moderate Parkinson's disease (GUT-PARFECT): a double-808 blind, placebo-controlled, randomised, phase 2 trial. EClinicalMedicine 71, 809 102563 (2024). 810 Bridi, R. et al. a-Keto Acids Accumulating in Maple Syrup Urine Disease 811 34. 812 Stimulate Lipid Peroxidation and Reduce Antioxidant Defences in Cerebral Cortex From Young Rats. Metab Brain Dis 20, 155–167 (2005). 813 814 35. Fernstrom, J. D. Branched-Chain Amino Acids and Brain Function. J Nutr 135, 1539S-1546S (2005). 815 36. Chen, S.-J. et al. Plasma metabolites of aromatic amino acids associate with 816 clinical severity and gut microbiota of Parkinson's disease. NPJ Parkinsons Dis 817 9, 165 (2023). 818 37. Venkatesan, D., Iyer, M., Narayanasamy, A., Siva, K. & Vellingiri, B. Kynurenine 819 820 pathway in Parkinson's disease—An update. eNeurologicalSci 21, 100270 821 (2020).38. Brito, I. L. et al. Transmission of human-associated microbiota along family and 822 social networks. Nat Microbiol 4, 964–971 (2019). 823 39. Hildebrand, F. et al. Dispersal strategies shape persistence and evolution of
- Bildebrand, F. *et al.* Dispersal strategies shape persistence and evolution of
   human gut bacteria. *Cell Host Microbe* 29, 1167-1176.e9 (2021).
- 40. O'Riordan, K. J. *et al.* Short chain fatty acids: Microbial metabolites for gut-brain axis signalling. *Mol Cell Endocrinol* **546**, 111572 (2022).
- 41. Matt, S. M. *et al.* Butyrate and Dietary Soluble Fiber Improve Neuroinflammation Associated With Aging in Mice. *Front Immunol* **9**, (2018).
- 42. Erny, D. *et al.* Host microbiota constantly control maturation and function of microglia in the CNS. *Nat Neurosci* **18**, 965–977 (2015).
- 43. Hoyles, L. *et al.* Microbiome–host systems interactions: protective effects of propionate upon the blood–brain barrier. *Microbiome* **6**, 55 (2018).

- Vinolo, M. A. R. *et al.* Suppressive effect of short-chain fatty acids on production
  of proinflammatory mediators by neutrophils. *J Nutr Biochem* 22, 849–855
  (2011).
- Singh, N. *et al.* Activation of Gpr109a, Receptor for Niacin and the Commensal
  Metabolite Butyrate, Suppresses Colonic Inflammation and Carcinogenesis. *Immunity* 40, 128–139 (2014).
- Kundi, Z. M. *et al.* Dietary Fiber from Oat and Rye Brans Ameliorate Western
  Diet–Induced Body Weight Gain and Hepatic Inflammation by the Modulation of
  Short-Chain Fatty Acids, Bile Acids, and Tryptophan Metabolism. *Mol Nutr Food Res* 65, (2021).
- Huang, L., Gao, L. & Chen, C. Role of Medium-Chain Fatty Acids in Healthy
  Metabolism: A Clinical Perspective. *Trends in Endocrinology & Metabolism* 32,
  351–366 (2021).
- 48. Hosomi, K., Kiyono, H. & Kunisawa, J. Fatty acid metabolism in the host and commensal bacteria for the control of intestinal immune responses and diseases. *Gut Microbes* **11**, 276–284 (2020).
- 49. Astarloa, R., Mena, M. A., Sánchez, V., de la Vega, L. & de Yébenes, J. G.
  Clinical and Pharmacokinetic Effects of a Diet Rich in Insoluble Fiber on
  Parkinson Disease. *Clin Neuropharmacol* **15**, 375–380 (1992).
- 50. Barichella, M. *et al.* Probiotics and prebiotic fiber for constipation associated with Parkinson disease. *Neurology* **87**, 1274–1280 (2016).
- 51. Cantu-Jungles, T. M. & Hamaker, B. R. New View on Dietary Fiber Selection for Predictable Shifts in Gut Microbiota. *mBio* **11**, (2020).
- 52. Ouyang, Y., Wu, Q., Li, J., Sun, S. & Sun, S. S-adenosylmethionine: A metabolite critical to the regulation of autophagy. *Cell Prolif* **53**, (2020).
- 53. Charlton, C. G. & Crowell, B. Parkinson's disease-like effects of S-: Effects of I-Dopa. *Pharmacol Biochem Behav* **43**, 423–431 (1992).
- 54. Hertel, J. *et al.* Integrated Analyses of Microbiome and Longitudinal Metabolome
  Data Reveal Microbial-Host Interactions on Sulfur Metabolism in Parkinson's
  Disease. *Cell Rep* 29, 1767-1777.e8 (2019).
- Sian, J. *et al.* Alterations in glutathione levels in Parkinson's disease and other
  neurodegenerative disorders affecting basal ganglia. *Ann Neurol* 36, 348–355
  (1994).
- Bjørklund, G., Peana, M., Maes, M., Dadar, M. & Severin, B. The glutathione
  system in Parkinson's disease and its progression. *Neurosci Biobehav Rev* 120,
  470–478 (2021).
- Nunes, C., Barbosa, R. M., Almeida, L. & Laranjinha, J. Nitric oxide and DOPACinduced cell death: From GSH depletion to mitochondrial energy crisis. *Molecular and Cellular Neuroscience* 48, 94–103 (2011).
- 873 58. Markowiak, P. & Śliżewska, K. Effects of Probiotics, Prebiotics, and Synbiotics
  874 on Human Health. *Nutrients* 9, 1021 (2017).
- 59. Sanders, M. E., Merenstein, D. J., Reid, G., Gibson, G. R. & Rastall, R. A. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. *Nat Rev Gastroenterol Hepatol* **16**, 605–616 (2019).
- 60. Sharma, R., Gupta, D., Mehrotra, R. & Mago, P. Psychobiotics: The Next-Generation Probiotics for the Brain. *Curr Microbiol* **78**, 449–463 (2021).
- 61. Desbonnet, L., Garrett, L., Clarke, G., Bienenstock, J. & Dinan, T. G. The probiotic Bifidobacteria infantis: An assessment of potential antidepressant properties in the rat. *J Psychiatr Res* **43**, 164–174 (2008).

- All rights reserved. No reuse allowed without permission.
- 883 62. Barrett, E., Ross, R. P., O'Toole, P. W., Fitzgerald, G. F. & Stanton, C. γ884 Aminobutyric acid production by culturable bacteria from the human intestine. J
  885 Appl Microbiol **113**, 411–417 (2012).
- Saito, K., Markey, S. P. & Heyes, M. P. Effects of immune activation on quinolinic
  acid and neuroactive kynurenines in the mouse. *Neuroscience* 51, 25–39
  (1992).
- 64. Čirstea, M. S. *et al.* A novel pathway of levodopa metabolism by commensal Bifidobacteria. *Sci Rep* **13**, 19155 (2023).
- 891 65. Svedlund, J., Sj□din, I. & Dotevall, G. GSRS?A clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. *Dig Dis Sci* 33, 129–134 (1988).
- 66. Venema, K., van Nuenen, M. H. M. C., van den Heuvel, E. G., Pool, W. & van der Vossen, J. M. B. M. The Effect of Lactulose on the Composition of the Intestinal Microbiota and Short-chain Fatty Acid Production in Human Volunteers and a Computer-controlled Model of the Proximal Large Intestine. *Microb Ecol Health Dis* **15**, 94–105 (2003).
- Aguirre, M., Jonkers, D. M. A. E., Troost, F. J., Roeselers, G. & Venema, K. In
  Vitro Characterization of the Impact of Different Substrates on Metabolite
  Production, Energy Extraction and Composition of Gut Microbiota from Lean and
  Obese Subjects. *PLoS One* 9, e113864 (2014).
- 68. Heinzmann, S. S. & Schmitt-Kopplin, P. Deep Metabotyping of the Murine
  Gastrointestinal Tract for the Visualization of Digestion and Microbial
  Metabolism. *J Proteome Res* 14, 2267–2277 (2015).
- 906 69. Dieterle, F., Ross, A., Schlotterbeck, G. & Senn, H. Probabilistic Quotient
  907 Normalization as Robust Method to Account for Dilution of Complex Biological
  908 Mixtures. Application in <sup>1</sup> H NMR Metabonomics. *Anal Chem* **78**, 4281–4290
  909 (2006).
- 70. Robinette, S. L. *et al.* Cluster Analysis Statistical Spectroscopy Using Nuclear
   Magnetic Resonance Generated Metabolic Data Sets from Perturbed Biological
   Systems. *Anal Chem* 81, 6581–6589 (2009).
- 91371.Bahram, M. *et al.*Metagenomic assessment of the global diversity and<br/>distribution of bacteria and fungi. *Environ Microbiol* **23**, 316–326 (2021).
- 915 72. Özkurt, E. *et al.* LotuS2: an ultrafast and highly accurate tool for amplicon 916 sequencing analysis. *Microbiome* **10**, 176 (2022).
- 73. Wood, D. E., Lu, J. & Langmead, B. Improved metagenomic analysis with
  Kraken 2. *Genome Biol* 20, 1–13 (2019).
- P19 74. Li, D., Liu, C.-M., Luo, R., Sadakane, K. & Lam, T.-W. MEGAHIT: an ultra-fast single-node solution for large and complex metagenomics assembly via succinct *de Bruijn* graph. *Bioinformatics* **31**, 1674–1676 (2015).
- 922 75. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. *Nat*923 *Methods* 9, 357–359 (2012).
- Steinegger, M. & Söding, J. MMseqs2 enables sensitive protein sequence
  searching for the analysis of massive data sets. *Nat Biotechnol* 35, 1026–1028
  (2017).
- 77. Saary, P., Forslund, K., Bork, P. & Hildebrand, F. RTK: efficient rarefaction analysis of large datasets. *Bioinformatics* **33**, 2594–2595 (2017).
- Pan, S., Zhao, X.-M. & Coelho, L. P. SemiBin2: self-supervised contrastive
  learning leads to better MAGs for short- and long-read sequencing. *Bioinformatics* 39, i21–i29 (2023).

- 79. Chklovski, A., Parks, D. H., Woodcroft, B. J. & Tyson, G. W. CheckM2: a rapid,
  scalable and accurate tool for assessing microbial genome quality using
  machine learning. *Nat Methods* 20, 1203–1212 (2023).
- 80. Nielsen, H. B. *et al.* Identification and assembly of genomes and genetic
  elements in complex metagenomic samples without using reference genomes. *Nat Biotechnol* **32**, 822–828 (2014).
- 81. Valles-Colomer, M. *et al.* The neuroactive potential of the human gut microbiota in quality of life and depression. *Nat Microbiol* **4**, 623–632 (2019).
- 82. McMurdie, P. J. & Holmes, S. phyloseq: An R Package for Reproducible
  Interactive Analysis and Graphics of Microbiome Census Data. *PLoS One* 8, e61217 (2013).
- 83. Leo Lahti, S. S. et al. Tools for microbiome analysis in R. Version 1.1.10013.
  944 URL: http://microbiome.github.com/microbiome.
- 945 84. Jari Oksanen, F. G. B. M. F. R. K. P. L. D. M. P. R. M. R. B. O. G. L. S. P. S. M.
  946 H. H. S. E. S. and H. W. vegan: Community Ecology Package. R package
  947 version 2.5-7. (2020).
- 85. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical
  and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society: Series B (Methodological)* 57, 289–300 (1995).
- 86. Hothorn, T., Hornik, K., Wiel, M. A. van de & Zeileis, A. Implementing a Class of Permutation Tests: The **coin** Package. *J Stat Softw* **28**, (2008).
- 87. Gavin L. Simpson, D. M. B. J. O. permute: Functions for Generating Restricted Permutations of Data. *https://github.com/gavinsimpson/permute* (2022).
- 88. Kim, S. ppcor: An R Package for a Fast Calculation to Semi-partial Correlation Coefficients. *Commun Stat Appl Methods* **22**, 665–674 (2015).
- 89. Wei T, S. V. R package 'corrplot': Visualization of a Correlation Matrix. (Version 0.92), *https://github.com/taiyun/corrplot.* (2021).
- 959

# 960 **Author contribution**

**JRB** conceptualised and performed the study, acquired funding, wrote the analytical 961 code and performed the formal analysis and drafted the manuscript. SR performed the 962 963 calprotectin and alpha 1 antitrypsin ELISA, helped in formal analysis and critically revised the manuscript. **SSH** performed the NMR metabolomics in faeces and urine 964 and helped in formal analysis of the respective data. AD helped in formal analysis of 965 the Enterosginatures. **DN** helped in formal analysis of the household effect. **MT** and 966 **DSL** formally analysed the food logs with the Nutritics software. **MCS** helped in 967 interpreting the SCFA and nutrition data and critically revised the manuscript. AN 968 funded the calprotectin and Alpha 1 Antitrypsin ELISA and critically revised the 969 manuscript. UW helped in recruiting the study participants and in interpreting the data 970

and critically revised the manuscript. FH performed the bioinformatic analyses of the
sequencing data, supervised the statistical code writing, interpreted all data and wrote
the manuscript with JRB. All authors read and approved the final manuscript.

974

#### 975 Acknowledgements

This study was funded by the Hilde-Ulrichs-Foundation for Parkinson's research. This 976 977 research was also supported by the BBSRC Institute Strategic Programme (ISP) Food Health BB/X011054/1 978 Microbiome and and its constituent project 979 BBS/E/F/000PR13631, the BBSRC Core Capability Grant BB/CCG2260/1 and its constituent project BBS/E/QU/23NB0006, ISP Decoding 980 the Biodiversity BBX011089/1, projects BBS/E/ER/230002A and BBS/E/ER/230002B, and Cellular 981 Genomics Cellular Genomics BBX011070/1, project BBS/E/ER/230001A. The funders 982 played no role in study design, data collection, analysis and interpretation of data, or 983 the writing of this manuscript. JRB was supported by a local grant (FEMHabil) at the 984 medical faculty of the University Hospital Bonn. FH was supported by European 985 Research Council H2020 StG (erc-stg-948219, EPYC). 986

987 We thank Lia Mareen Taube for her support during the study performance.

988

## 989 Competing interests

All authors declare no financial or non-financial competing interests.